(19)
(11) EP 1 072 255 B8

(12) CORRECTED EUROPEAN PATENT SPECIFICATION
Note: Bibliography reflects the latest situation

(15) Correction information:
Corrected version no 1 (W1 B1)

(48) Corrigendum issued on:
13.04.2005 Bulletin 2005/15

(45) Mention of the grant of the patent:
05.01.2005 Bulletin 2005/01

(21) Application number: 00117452.3

(22) Date of filing: 24.10.1994
(51) International Patent Classification (IPC)7: A61K 9/16, A61K 31/16, A61K 31/35, A61K 38/23, A61K 38/28

(54)

Oral delivery system for desferrioxamine, insulin and cromolyn sodium

Orales Verabreichungssystem für Desferrioxamin, Insulin und Cromolyn-Natrium

Système d'administration orale de deferrioxamine, d'insuline et de cromolyne sodique

(84) Designated Contracting States:
AT BE CH DE DK ES FR GB GR IE IT LI LU MC NL PT SE

(30) Priority: 26.10.1993 US 143571
16.12.1993 US 168776

(43) Date of publication of application:
31.01.2001 Bulletin 2001/05

(62) Application number of the earlier application in accordance with Art. 76 EPC:
94932077.4 / 0726771

(73) Proprietor: Emisphere Technologies, Inc.
Tarrytown, New York 10591-6715 (US)

(72) Inventors:
  • Milstein, Sam J.
    Larchmont, NY 10538 (US)
  • Barantsevitch, Evgueni N.
    Scarsdale, NY 10583 (US)

(74) Representative: Grünecker, Kinkeldey, Stockmair & Schwanhäusser Anwaltssozietät 
Maximilianstrasse 58
80538 München
80538 München (DE)


(56) References cited: : 
EP-A- 0 418 642
GB-A- 999 583
US-A- 4 442 090
 DE-A- 2 722 917
GB-A- 2 095 994
US-A- 4 925 673
   
       
    Note: Within nine months from the publication of the mention of the grant of the European patent, any person may give notice to the European Patent Office of opposition to the European patent granted. Notice of opposition shall be filed in a written reasoned statement. It shall not be deemed to have been filed until the opposition fee has been paid. (Art. 99(1) European Patent Convention).